Fibroblast growth factor 23 and 25(OH)D levels are related to abdominal obesity and cardiovascular risk in patients with polycystic ovarian syndrome

References

• Norman RJ, Davies MJ, Lord J, et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002;13(6):251–257.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J ClinEndocrinolMetab. 2008;93(1):162–168.
   PubMed Web of Science ®Google Scholar
• Vigil P, Contreras P, Alvarado J, et al. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum Reprod. 2007;22(11):2974–2980.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H, San Millan J. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metabol. 2007;18(7):266–272.
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes. 2002;26(7):883–896.
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, et al. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG. 2006;113(10):1203–1209.
   PubMed Web of Science ®Google Scholar
• Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, et al. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev. 2012;23:37–46.
   PubMed Web of Science ®Google Scholar
• Kuro M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008;19:239–245.
   PubMed Web of Science ®Google Scholar
• Kuro-O M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.
   PubMed Web of Science ®Google Scholar
• Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829–1833.
   PubMed Web of Science ®Google Scholar
• Kuro M. Overview of the FGF23-Klotho axis. PediatrNephrol. 2010;25(4):583–590.
   Google Scholar
• Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–774.
   PubMed Web of Science ®Google Scholar
• Jing X, Li DQ, Olofsson CS, et al. Cav2.3 calcium channels control second-phase insulin release. J Clin Invest. 2005;115(1):146–154.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. FertilSteril. 2004;81(1):19–25.
   Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J ClinEndocrinolMetab. 2010;95(5):2038–2049.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J ClinEndocrinol Metab. 2011;96(7):1911–1930.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. International diabetes federation task force on epidemiology and prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Stöhr R, Schuh A, Heine GH, et al. FGF23 in cardiovascular disease: innocent bystander or active mediator? Front Endocrinol (Lausanne). 2018;9:351.
   PubMed Web of Science ®Google Scholar
• Zwakenberg SR, van der Schouw YT, Schalkwijk CG, et al. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc Diabetol. 2018;17(1):45.
   PubMedGoogle Scholar
• Quercioli A, Montecucco F, Bertolotto M, et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. Eur J Clin Invest. 2010;40(7):645–654.
   PubMed Web of Science ®Google Scholar
• Lu X, Hu MC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis. 2017;3(1):15–23.
   Web of Science ®Google Scholar
• Elsheikh N, Sherif N, Zeid SA, et al. The link between bone disease and cardiovascular complications in hemodialysis patients. Electron Physician. 2016;8(6):2483–2488.
   PubMedGoogle Scholar
• Kuro-O M. Klotho and endocrine fibroblast growth factors: marker of chronic kidney disease progression and cardiovascular complications? Nephrol Dial Transplant. 2019;34(1):15–21.
   PubMed Web of Science ®Google Scholar
• Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med. 2010;152(10):640–648.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kleber ME, Vervloet MG, et al. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2014;237(1):53–59.
   PubMed Web of Science ®Google Scholar
• Souma N, Isakova T, Lipiszko D, et al. Fibroblast growth factor 23 and cause-specific mortality in the general population: the Northern Manhattan study. J ClinEndocrinol Metab. 2016;101(10):3779–3786.
   PubMed Web of Science ®Google Scholar
• Sit D, Tanrıverdi E, Kayabasi H, et al. Is FGF23 effective on insulin resistance in individuals with metabolic syndrome? Horm Mol BiolClin Investig. 2018;35(2).
   Google Scholar
• Bär L, Feger M, Fajol A, et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci USA. 2018;115(22):5804–5809.
   PubMed Web of Science ®Google Scholar
• Gateva A, Assyov Y, Tsakova A, et al. Prediabetes is characterized by higher FGF23 levels and higher prevalence of vitamin D deficiency compared to normal glucose tolerance subjects. Horm Metab Res. 2019;51(2):106–111.
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008;93:1276–1284.
   PubMed Web of Science ®Google Scholar
• Talbott E, Zborowski J, Rager J, et al. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? VHRM. 2008;4(2):453–462.
   Google Scholar
• Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87(5):2013–2017.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Martínez-García MA, et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur J Endocrinol. 2008;159(3):225–232.
   PubMed Web of Science ®Google Scholar
• Saklamaz A, Calan M, Yilmaz O, et al. Polycystic ovary syndrome is associated with increased osteopontin levels. Eur J Endocrinol. 2016;174(4):415–423.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou W, Wu C, et al. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study. Reprod Biol Endocrinol. 2018;16(1):31.
   PubMedGoogle Scholar
• Kan K, Kızılgül M, Çulha C, et al. Fibroblast growth factor-23 concentrations in polycystic ovary syndrome. Turk J Biochem. 2018;43(1):83.
   Web of Science ®Google Scholar
• Marthi A, Donovan K, Haynes R, et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. JASN. 2018;29(7):2015–2027.
   Web of Science ®Google Scholar
• Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77(3):343–350.
   PubMed Web of Science ®Google Scholar
• Moini A, Shirzad N, Ahmadzadeh M, et al. Comparison of 25-hydroxyvitamin D and calcium levels between polycystic ovarian syndrome and normal women. Int J Fertil Steril. 2015;9(1):1–8.
   PubMed Web of Science ®Google Scholar
• Krul-Poel YH, Snackey C, Louwers Y, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol. 2013;169(6):853–665.
   PubMed Web of Science ®Google Scholar
• Tsakova A, Gateva A, Kamenov Z. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res. 2012;82(6):399–404.
   PubMed Web of Science ®Google Scholar